Patents Assigned to Mati Therapeutics, Inc.
-
Publication number: 20170202853Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.Type: ApplicationFiled: April 3, 2017Publication date: July 20, 2017Applicant: Mati Therapeutics Inc.Inventors: Suzanne Cadden, Yong Hao, Deepank Utkhede, Valery Rubinchik, Charles Richard Kjelbotn
-
Patent number: 9610194Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.Type: GrantFiled: February 14, 2014Date of Patent: April 4, 2017Assignee: Mati Therapeutics Inc.Inventors: Eugene De Juan, Jr., Stephen Boyd, Hanson S. Gifford, III, Mark Deem, Cary J. Reich
-
Patent number: 9610271Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.Type: GrantFiled: December 20, 2013Date of Patent: April 4, 2017Assignee: Mati Therapeutics Inc.Inventors: Suzanne Cadden, Yong Hao, Deepank Utkhede, Valery Rubinchik, Charles Richard Kjellbotn
-
Patent number: 9549852Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.Type: GrantFiled: September 18, 2015Date of Patent: January 24, 2017Assignee: Mati Therapeutics Inc.Inventors: Eugene de Juan, Jr., Stephen Boyd, Cary Reich, Alan Rapacki, Hanson S Gifford, Mark Deem
-
Patent number: 9463114Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.Type: GrantFiled: August 29, 2014Date of Patent: October 11, 2016Assignee: Mati Therapeutics Inc.Inventors: Steven A. Odrich, Liane C. Glazer
-
Patent number: 9445944Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.Type: GrantFiled: February 28, 2014Date of Patent: September 20, 2016Assignee: Mati Therapeutics Inc.Inventors: Alan R. Rapacki, Valery Rubinchik, John B. Holds, Sylvie Sim, Danny Shen
-
Publication number: 20160166430Abstract: Lacrimal implants and related methods providing secure retention within the lacrimal punctum of an eye are described. The lacrimal implants can comprise a implant body configured for at least partial insertion through the lacrimal punctum and into a lacrimal canaliculus. The implant body can include a deformable retention structure that can be configured to substantially encapsulate an expandable retention element. In some examples, the expandable retention element can include a fluid absorbing material, which can be exposed to fluid such as via a fluid permeable retainer or a fluid permeable aperture. As the fluid absorbing material retains fluid (i.e., upon acceptance of fluid into the retention structure), its size increases and its shape can change to urge one or more portions of the retention structure outward, such as against a wall of the lacrimal canaliculus, thereby securely retaining the lacrimal implant within the punctum.Type: ApplicationFiled: December 14, 2015Publication date: June 16, 2016Applicant: Mati Therapeutics Inc.Inventors: Rachna Jain, Robert W. Shimizu
-
Publication number: 20150367037Abstract: Lacrimal implants, methods of making lacrimal implants, and methods of treating ocular, respiration or other diseases or disorders using lacrimal implants are disclosed.Type: ApplicationFiled: August 21, 2015Publication date: December 24, 2015Applicant: Mati Therapeutics Inc.Inventors: Sylvie Sim, Rachna Jain, Kathleen Farinas
-
Patent number: 9216108Abstract: Lacrimal implants and related methods providing secure retention within the lacrimal punctum of an eye are described. The lacrimal implants can comprise a implant body configured for at least partial insertion through the lacrimal punctum and into a lacrimal canaliculus. The implant body can include a deformable retention structure that can be configured to substantially encapsulate an expandable retention element. In some examples, the expandable retention element can include a fluid absorbing material, which can be exposed to fluid such as via a fluid permeable retainer or a fluid permeable aperture. As the fluid absorbing material retains fluid (i.e., upon acceptance of fluid into the retention structure), its size increases and its shape can change to urge one or more portions of the retention structure outward, such as against a wall of the lacrimal canaliculus, thereby securely retaining the lacrimal implant within the punctum.Type: GrantFiled: February 17, 2009Date of Patent: December 22, 2015Assignee: Mati Therapeutics Inc.Inventors: Rachna Jain, Robert W. Shimizu
-
Patent number: 9180045Abstract: A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.Type: GrantFiled: April 7, 2011Date of Patent: November 10, 2015Assignee: Mati Therapeutics Inc.Inventor: Eliot Lazar
-
Patent number: 9168222Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.Type: GrantFiled: April 29, 2014Date of Patent: October 27, 2015Assignee: Mati Therapeutics Inc.Inventors: Eugene De Juan, Jr., Stephen Boyd, Cary Reich, Alan Rapacki, Hanson S Gifford, Mark Deem
-
Patent number: 9132088Abstract: Lacrimal implants, methods of making lacrimal implants, and methods of treating ocular, respiration or other diseases or disorders using lacrimal implants are disclosed.Type: GrantFiled: April 29, 2009Date of Patent: September 15, 2015Assignee: Mati Therapeutics Inc.Inventors: Sylvie Sim, Rachna Jain, Kathleen Farinas
-
Publication number: 20150224200Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.Type: ApplicationFiled: January 16, 2015Publication date: August 13, 2015Applicant: Mati Therapeutics Inc.Inventors: Eugene de Juan, JR., Stephen Boyd, Hanson S. Gifford, III, Mark Deem, Cary Reich
-
Patent number: 9011361Abstract: This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.Type: GrantFiled: September 5, 2008Date of Patent: April 21, 2015Assignee: Mati Therapeutics Inc.Inventors: Eugene de Juan, Jr., Stephen Boyd, Cary J. Reich, Christopher V. Cardenas, Tommy Jewell, Lorrie Ma, Ngoc-Tuan Nguyen
-
Publication number: 20140350103Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.Type: ApplicationFiled: December 20, 2013Publication date: November 27, 2014Applicant: Mati Therapeutics, Inc.Inventors: Suzanne Cadden, Yong Hao, Deepank Utkhede, Valery Rubinchki, Charles Richard Kjellbotn
-
Publication number: 20140236293Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: Mati Therapeutics Inc.Inventors: Eugene De Juan, JR., Stephen Boyd, Cary Reich, Alan Rapacki, Hanson S. Gifford, Mark Deem
-
Patent number: 8795711Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.Type: GrantFiled: April 2, 2007Date of Patent: August 5, 2014Assignee: Mati Therapeutics Inc.Inventors: Eugene de Juan, Jr., Cary Reich, Stephen Boyd, Hanson G. Gifford, III, Mark Deem
-
Publication number: 20140186420Abstract: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.Type: ApplicationFiled: December 5, 2013Publication date: July 3, 2014Applicant: Mati Therapeutics, Inc.Inventors: Deepank Utkhede, Robert W. Shimizu, Rachna Jain, Stephen Boyd, Hanson S. Gifford, Eugene De Juan, JR., Cary J. Reich
-
Publication number: 20140180253Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.Type: ApplicationFiled: February 28, 2014Publication date: June 26, 2014Applicant: Mati Therapeutics Inc.Inventors: Alan R. Rapacki, Valery Rubinchik, John B. Holds, Sylvie Sim, Danny Shen
-
Publication number: 20140161863Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.Type: ApplicationFiled: February 14, 2014Publication date: June 12, 2014Applicant: Mati Therapeutics, Inc.Inventors: Eugene De Juan, JR., Stephen Boyd, Hanson S. Gifford, III, Mark Deem, Cary J. Reich